Cheaper drug to treat wet AMD increases risk of serious eye inflammation
A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.